Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akero Therapeutics

53.84
+0.18000.34%
Post-market: 53.890.0500+0.09%19:52 EDT
Volume:1.58M
Turnover:84.69M
Market Cap:4.31B
PE:-14.24
High:53.87
Open:53.67
Low:53.63
Close:53.66
52wk High:58.40
52wk Low:21.34
Shares:79.99M
Float Shares:67.77M
Volume Ratio:0.33
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7801
EPS(LYR):-3.7544
ROE:-31.14%
ROA:-20.36%
PB:4.20
PE(LYR):-14.34

Loading ...

Jonathan Young, Chief Operating Officer, Reports Disposal of Common Shares of Akero Therapeutics Inc

Reuters
·
Sep 05

Akero Therapeutics Inc. to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Aug 28

Akero Therapeutics Announces Promising Phase 2b HARMONY Trial Results Showing Efruxifermin Reduces Liver Fibrosis in Pre-cirrhotic MASH Patients

Reuters
·
Aug 15

Akero Therapeutics Announces Lancet Publication of the Phase 2B Harmony Clinical Trial Demonstrating 96 Weeks Treatment With Efx Reduced Liver Fibrosis in Patients With Pre-Cirrhotic Mash

THOMSON REUTERS
·
Aug 15

Andrew Cheng, President and CEO, Reports Disposal of Akero Therapeutics Inc. Common Shares

Reuters
·
Aug 14

Director Jane Henderson Reports Disposal of Common Shares in Akero Therapeutics Inc

Reuters
·
Aug 13

Akero Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Aug 08

Akero Therapeutics Q2 Net Income USD -70.505 Million Vs. IBES Estimate USD -70.1 Million

Reuters
·
Aug 08

Earnings Flash (AKRO) Akero Therapeutics Posts Q2 Net Loss $0.86 a Share, vs. FactSet Est of $0.96 Loss

MT Newswires Live
·
Aug 08

Akero Therapeutics Q2 EPS $(0.86) Beats $(0.93) Estimate

Benzinga
·
Aug 08

Akero Therapeutics Reports Increased Q2 2025 Operating Expenses, No Revenue or Profit Data Provided

Reuters
·
Aug 08

Akero Therapeutics Q2 Basic EPS USD -0.86

THOMSON REUTERS
·
Aug 08

Akero Therapeutics Q2 Net Income USD -70.505 Million VS. Ibes Estimate USD -70.1 Million

THOMSON REUTERS
·
Aug 08

Chief Scientific Officer Timothy Rolph Reports Disposal of Akero Therapeutics Inc. Common Shares

Reuters
·
Aug 07

BB Biotech AG Reports Q2 2025 Net Loss of CHF 100 Million; USD Share Price Up 10.2%, Currency Drag Impacts CHF Performance

Reuters
·
Jul 25

Chief Development Officer Catriona Yale Reports Disposal of Common Shares in Akero Therapeutics Inc

Reuters
·
Jul 19

CEO Andrew Cheng Reports Disposal of Common Shares of Akero Therapeutics Inc

Reuters
·
Jul 12

Chief Scientific Officer Timothy Rolph Reports Disposal of Common Shares of Akero Therapeutics Inc

Reuters
·
Jul 10

Patrick Lamy, Senior VP of Commercial Strategy, Reports Disposal of Common Shares of Akero Therapeutics Inc

Reuters
·
Jul 04

Scott A. Gangloff, Chief Technology Officer, Reports Disposal of Common Shares of Akero Therapeutics Inc

Reuters
·
Jun 21